Senaparib

Generic Name: Senaparib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₀F_₂N_₆O_₃

CAS Number: 1401682-78-7

Unique Ingredient Identifier: MNZ4OP95CF

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Senaparib in Combination With Temozolomide

Phase 2

Not yet recruiting

Conditions: Ovary Cancer
Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: Senaparib
Drug: Temozolomide

First Posted Date: 2024-10-01

Last Posted Date: 2024-12-11

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 18

Registration Number: NCT06617923

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

Phase 2

Conditions: mCRPC

Interventions: Drug: Placebo
Drug: Senaparib

First Posted Date: 2021-03-30

Last Posted Date: 2021-12-16

Lead Sponsor: Impact Therapeutics, Inc.

Target Recruit Count: 285

Registration Number: NCT04822961

Locations: 🇨🇳
IMPACT Therapeutics Inc., Shanghai, Shanghai, China
🇦🇺
Macquarie University Hospital, Sydney, Australia
🇦🇺
Cabrini Hospital, Melbourne, Australia

and more 3 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy